Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells

Journal of Immunology

Volumn 172, Issue 11, 2004, Pages 7206-7211

  Ayyoub, Maha ^a   Hesdorffer, Charles S ^a   Metthez, Geevieve ^a   Stevaovic, Stefa ^b   Ritter, Gerd ^c   Che, Yao Tseg ^d   Old, Lloyd J ^c   Speiser, Daiel ^e   Cerottii, Jea Charles ^f   Valmori, Daila ^a  

^a Columbia Univ Coll of Phys/Surgs ^*  (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; HLA DP ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DENDRITIC CELL; GENE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; PRIORITY JOURNAL; SSX 2 GENE; SYNOVIAL SARCOMA X BREAKPOINT 2 GENE; T LYMPHOCYTE; TISSUE CULTURE; TUMOR IMMUNOLOGY;

EID: 2442694023     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.11.7206     Document Type: Article

References (34)

1. Robbins, P. F., M. El-Gamil, Y. F. Li, Y. Kawakami, D. Loftus, E. Appella, and S. A. Rosenberg. 1996. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183:1185.
2. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
3. Coulie, P. G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J. P. Szikora, et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
4. Scanlan, M. J., A. O. Gure, A. A. Jungbluth, L. J. Old, and Y. T. Chen. 2002. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188:22.
5. Old, L. J. 2001. Cancer/testis (CT) antigens: a new link between gametogenesis and cancer. Cancer Immun. 1:1.
6. + T cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 60:4499.
7. 254-262 in melanoma. Cancer Res. 61:501.
8. Klenerman, P., V. Cerundolo, and P. R. Dunbar. 2002. Tracking T cells with tetramers: new tales from new tools. Nat. Rev. Immunol. 2:263.
9. + T lymphocytes. J. Exp. Med. 189:767.
10. + T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc. Natl. Acad. Sci. USA 98:3964.
11. + T cells in antitumor immunity. Trends Immunol. 22:269.
12. Naka, N., N. Araki, H. Nakanishi, K. Itoh, M. Mano, S. Ishiguro, D. R. de Bruijn, A. Myoui, T. Ueda, and H. Yoshikawa. 2002. Expression of SSX genes in human osteosarcomas. Int. J. Cancer. 98:640.
13. Tureci, O., U. Sahin, I. Schobert, M. Koslowski, H. Scmitt, H. J. Schild, F. Stenner, G. Seitz, H. G. Rammensee, and M. Pfreundschuh. 1996. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res. 56:4766.
14. Tureci, O., Y. T. Chen, U. Sahin, A. O. Gure, C. Zwick, C. Villena, S. Tsang, G. Seitz, L. J. Old, and M. Pfreundschuh. 1998. Expression of SSX genes in human tumors. Int. J. Cancer. 77:19.
15. Clark, J., P. J. Rocques, A. J. Crew, S. Gill, J. Shipley, A. M. Chan, B. A. Gusterson, and C. S. Cooper. 1994. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat. Genet. 7:502.
16. Crew, A. J., J. Clark, C. Fisher, S. Gill, R. Grimer, A. Chand, J. Shipley, B. A. Gusterson, and C. S. Cooper. 1995. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J. 14:2333.
17. Rubio-Godoy, V., M. Ayyoub, V. Dutoit, C. Servis, A. Schink, D. Rimoldi, P. Romero, J. C. Cerottini, R. Simon, Y. Zhao, et al. 2002. Combinatorial peptide library-based identification of peptide ligands for tumor-reactive cytolyfic T lymphocytes of unknown specificity. Eur. J. Immunol. 32:2292.
18. Ayyoub, M., S. Stevanovic, U. Sahin, P. Guillaume, C. Servis, D. Rimoldi, D. Valmori, P. Romero, J. C. Cerottini, H. G. Rammensee, et al. 2002. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J. Immunol. 168:1717.
19. + T cells are selectively expanded during immune responses to antigen expressing tumors in melanoma patients. Cancer Res. 63:5601.
20. Stockert, E., E. Jager, Y. T. Chen, M. J. Scanlan, I. Gout, J. Karbach, M. Arand, A. Knuth, and L. J. Old. 1998. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187:1349.
21. Yu, Z., and N. P. Restifo. 2002. Cancer vaccines: progress reveals new complexities. J. Clin. Invest. 110:289.
22. Parmiani, G., C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F. M. Marincola, and A. Anichini. 2002. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. 94:805.
23. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells. Immunity 12:677.
24. + T-helper and a T-killer cell. Nature 393:474.
25. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA 96:8633.
26. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
27. Albert, M. L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86.
28. + T cells. J. Immunol. Methods 268:71.
29. Halder, T., G. Pawelec, A. F. Kirkin, J. Zeuthen, H. E. Meyer, L. Kun, and H. Kalbacher. 1997. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res. 57:3238.
30. + T cells. J. Exp. Med. 189:757.
31. Wang, R. F., X. Wang, A. C. Atwood, S. L. Topalian, and S. A. Rosenberg. 1999. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284:1351.
32. Gaschet, J., A. Lim, L. Liem, R. Vivien, M. M. Hallet, J. L. Harousseau, J. Even, E. Goulmy, M. Bonneville, N. Milpied, et al. 1996. Acute graft versus host disease due to T lymphocytes recognizing a single HLA-DPB1*0501 mismatch. J. Clin. Invest. 98:100.
33. + cytolytic T lymphocytes. Cancer Res. 60:6272.
34. Castelli, F. A., C. Buhot, A. Sanson, H. Zarour, S. Pouvelle-Moratille, C. Nonn, H. Gahery-Segard, J. G. Guillet, A. Menez, B. Georges, et al. 2002. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J. Immunol. 169:6928.